Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Current Deferred Revenue (2016 - 2025)

BioCorRx (BICX) has disclosed Current Deferred Revenue for 16 consecutive years, with $56590.0 as the latest value for Q2 2025.

  • Quarterly Current Deferred Revenue changed N/A to $56590.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $56590.0 through Jun 2025, changed N/A year-over-year, with the annual reading at $56590.0 for FY2024, 1299.01% up from the prior year.
  • Current Deferred Revenue hit $56590.0 in Q2 2025 for BioCorRx, roughly flat from $56590.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $81099.0 in Q3 2021 to a low of $4045.0 in Q2 2023.
  • Historically, Current Deferred Revenue has averaged $33804.1 across 5 years, with a median of $34981.0 in 2021.
  • Biggest five-year swings in Current Deferred Revenue: crashed 92.64% in 2023 and later soared 1299.01% in 2024.
  • Year by year, Current Deferred Revenue stood at $34981.0 in 2021, then grew by 6.63% to $37301.0 in 2022, then tumbled by 89.16% to $4045.0 in 2023, then skyrocketed by 1299.01% to $56590.0 in 2024, then changed by 0.0% to $56590.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for BICX at $56590.0 in Q2 2025, $56590.0 in Q4 2024, and $4045.0 in Q1 2024.